Mandates Ryoncil® CoverageNEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback